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Abstract
Aims: UK guidance was recently developed for the treatment of anal cancer using intensity-modulated radiotherapy (IMRT). We audited the current use of
radiotherapy in UK cancer centres for the treatment of anal cancer against such guidance. We describe the acute toxicity of IMRT in comparison with patient
population in the audit treated with two-phase conformal radiotherapy and the previous published data from two-phase conformal radiotherapy, in the UK
ACT2 trial.
Materials and methods: A Royal College of Radiologists’ prospective national audit of patients treated with radiotherapy in UK cancer centres was carried out
over a 6 month period between February and July 2015.
Results: Two hundred and forty-two cases were received from 40/56 cancer centres (71%). In total, 231 (95%) underwent full dose radiotherapy with pro-
phylactic nodal irradiation. Of these, 180 (78%) received IMRT or equivalent, 52 (22%) two-phase conformal (ACT2) technique. The number of interruptions in
radiotherapy treatment in the ACT2 trial was 15%. Interruptions were noted in 7% (95% conﬁdence interval 0e14%) of courses receiving two-phase conformal
and 4% (95% conﬁdence interval 1e7%) of those receiving IMRT. The percentage of patients completing the planned radiotherapy dose, irrelevant of gaps, was
90% (95% conﬁdence interval 82e98%) and 96% (95% conﬁdence interval 93e99%), in two-phase conformal and IMRT respectively. The toxicity reported in the
ACT2 trial, in patients receiving two-phase conformal in the audit and in patients receiving IMRT in the audit was: any toxic effect 71%, 54%, 48%, non-
haematological 62%, 49%, 40% and haematological 26%, 13%, 18%, respectively.
Conclusions: IMRT implementation for anal cancer is well underway in the UK with most patients receiving IMRT delivery, although its usage is not yet
universal. This audit conﬁrms that IMRT results in reduced acute toxicity and minimised treatment interruptions in comparison with previous two-phase
conformal techniques.
 2016 The Royal College of Radiologists. Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/
by/4.0/).
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Anal cancer is a relatively rare tumour with an increasing
incidence [1]. It is associated with infection with high-riskAuthor for correspondence: R. Muirhead, Oxford University Hospitals
NHS Trust, Department of Oncology, Churchill Hospital, Oxford, UK. Tel:
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org/licenses/by/4.0/).subtypes of human papilloma viruses [2]. The ACT2 study
set the standard for radical chemoradiotherapy (CRT) in
anal squamous cell carcinoma in the UK, with a 3 year
disease-free survival of 73% [3]. However, the radiotherapy
techniques available at the time of trial design, large ante-
rioreposterior/posterioreanterior ﬁelds, were associated
with signiﬁcant acute toxicity, particularly in the skin and
perineum. Although relatively modest total radiation doses
were used, this toxicity often entailed long breaks inis is an open access article under the CC BY license (http://creativecommons.
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considerable late pelvic radiation morbidity [4e8].
Intensity-modulated radiotherapy (IMRT) conforms
doses around irregular volumes using multiple beams and
varying dose rates. This minimises dose to normal organs
with the aim of reducing toxicity. The Radiation Therapy
Oncology Group (RTOG) 0529 single arm phase II study
conﬁrmed reduced acute toxicity with IMRT in radical anal
CRT; when retrospectively compared with the previous
RTOG 9811 trial, where radiotherapy was delivered con-
formally using a shrinking ﬁeld technique [9]. RTOG 0529
delivered 54 Gy and 45 Gy in 30 fractions to primary tumour
and prophylactic lymph nodes, respectively, in locally
advanced disease and 50 Gy and 42 Gy in 28 fractions,
respectively, to early disease.
In 2012, the UK Department of Health recommended
that all patients who could beneﬁt from reduced treatment
toxicity through the use of IMRT should be offered this
treatment [10]. However, the implementation of IMRT for
any given indication brings a number of challenges. Con-
verting ACT2 radiotherapy to an IMRT protocol required
consideration of doses, volumes and technique [11].
Implementation without due care and quality control can
result in geographical miss; potentially reducing cure rates
and/or increasing toxicity. Some authors have questioned
the uncritical adoption of IMRT, raising concerns regarding
the steep and long learning curve required for the technique
to be perfected and the lack of quality assurance [12]. Del-
horme et al. [13] reported improved outcomes with the use
of guidelines. However, in RTOG 0529, despite the stringent
protocolised setting of a clinical trial, 81% of plans submit-
ted for central review were rejected at ﬁrst review and 46%
required multiple revisions [9]. They also reported corre-
lations between minor or major deviations from protocol
and outcomes; patients who had aminor ormajor deviation
in dose to small bowel had a increased rate of Grade 2þ
toxicity. As such, it is vital in the multicentre implementa-
tion of IMRT to agree detailed homogeneous delivery
guidelines, encourage education and mentoring; and
incorporate adequate quality assurance.
To investigate the implementation of IMRT in anal cancer
in the UK, the Royal College of Radiologists (RCR) surveyed
58 centres in November 2013, requesting information on
current radiotherapy delivery techniques used for anal
cancer and the ability and time frames for implementing
IMRT [14]. The results showed that IMRT implementation
had begun in a sporadic manner with different delineation,
doses and constraints being used. The results of the survey
are available as supplementary material. This highlighted
the difﬁculties of implementing a new technique in a rare
cancer with limited supporting evidence and few treating
clinicians. As such, a working group of specialist clinicians
in anal cancer was convened, supported by the Anorectal
Clinical Studies Sub Group (CSG) of the National Cancer
Research Institute (NCRI), to develop consensus guidance
detailing standard radiotherapy volume delineation, dose
and fractionation based on the volumes and doses used in
the ACT2 study [15]. This was presented at the annual NCRI
and other meetings [16] and highlighted in an editorial [14].A national audit was initiated in order to assess the
implementation of this challenging technique. Further-
more, future clinical trials will require an IMRT platform,
and as such an IMRT solution was required, ideally with
implementation and an audit of implementation before the
development of further studies.
The audit presented here was carried out 2 years after
the initial survey with the aims:
(i) To benchmark the national delivery of radiotherapy in
anal cancer and identify potential for improvements.
(ii) To compare UK practice with National Comprehensive
Cancer Network (NCCN) and ESMO-ESSO-ESTRO
guidance.
(iii) To assess whether the number of patients receiving
IMRT are in keeping with National Radiotherapy
Implementation Group (NRIG) IMRT
recommendations.
(iv) To document the compliance with suggested UK IMRT
guidance.
(v) To describe the acute toxicity of IMRTas per UK guidance
in comparisonwith previous ACT2 published toxicity.
(vi) To provide a UK-wide standard of care to optimise the
opportunities for clinical research and improvements
in this disease in the future at a national level.Materials and Methods
We aimed to collect prospective data on all patients with
a diagnosis of anal cancer, in all UK National Health Service
cancer centres, starting radiotherapy over a 6 month period
from 9 February to 27 July 2015. Patient demographic data
included the age and gender of patient, whether or not they
underwent a pre-treatment stoma, HIV and smoking status.
Tumour demographic data included pathology, level of dif-
ferentiation, stage and site of primary and lymph nodes.
Details of chemotherapy and radiotherapy treatment and
weekly CTC acute toxicity (v4.03, 2010) during treatment
were collected. RTOG grading was used for skin toxicity.
Finally patients were asked to complete a European Orga-
nization for Research and Treatment of Cancer (EORTC)
questionnaire to document the baseline patient-reported
outcomes of disease and treatment symptoms [17,18]. Data
points collected are documented within supplementary
material. A speciﬁcally developedweb-based data collection
form was constructed using Snap WebHost Professional
survey software. The data form was reviewed by the RCR
Clinical Oncology Audit Committee and, after revision,
piloted in ﬁve centres. Clinical oncology audit leads acted as
points of contact between the RCR and participating centres.
Data were reviewed by RM and DG. On review of the
submitted data, grade 3 toxicity was noted if: it resulted in
an admission, an interruption or discontinuation of
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theweekly grading. Where a total white cell count had been
submitted instead of a neutrophil count, the white cell
count was divided by two to calculate an approximate
neutrophil count that was used for analysis (as neutrophils
make up approximately 50% of the white cell count, this
method was deemed an appropriate estimate of the
neutrophil count [19]). In the case of discordance between
lymph node location and stage, the stage was manually
corrected in keeping with the site and number of lymph
nodes in accordance with AJCC 7th edition, 2010 [20]. The
maximum toxic effect grade was used for each patient and
each event type. An interruption in radiotherapy treatment
was deﬁned as any extension to the treatment,>2 days over
the planned overall treatment time, as per RCR guidance on
interruptions suggesting that any gap over 2 days requires
compensation [21].
Data analysis was undertaken using Microsoft Ofﬁce
Excel 2013 (Microsoft Corporation, CA, USA) and Graphpad
(www.graphpad.com). All analyses are intention-to-treat
unless otherwise speciﬁed.Results
Two hundred and forty-two cases were received from 40
of 56 (71%) UK radiotherapy centres. Two centres replied
that they refer anal cancer patients elsewhere. The number
of cases received from contributing centres varied from one
to 13 (median six). Cases were categorised as either ACT2
style (for the purposes of this audit termed ‘two-phase
conformal CRT’[AQ1]) or IMRT. Within the two-phase
conformal CRT group and the IMRT groups, the number of
cases varied from one to 11 (median three) and one and 12
(median three), respectively. This is because eight centres
were contributing both two-phase conformal CRT and IMRT
data. Of the four centres submitting 10 cases; three
centres used solely IMRT for radical treatment, one used
solely two-phase conformal CRT. Tables 1 and 2 detail pa-
tient and tumour demographics, respectively. The groups
were relatively well balanced with non-signiﬁcant differ-
ences in gender (11 men versus 41 women in the two-phase
conformal CRT group and 47 men versus 110 women in the
IMRT treated group; x2 P ¼ 0.284), pre-treatment stoma
formation (11/52 ¼ 21% with two-phase conformal CRT and
24/157 ¼ 15% in the IMRT group, x2 P ¼ 0.391) and
equivalent T and N stages. There was a signiﬁcant
difference in the proportion that were conﬁrmed smokers
(21/52 ¼ 40% in the two-phase conformal CRT and 38/
157 ¼ 24% in the IMRT group; x2 P ¼ 0.033). Although
exact proportions differed, rates of T3/4 were similar in
both groups (48% versus 47%). Slightly more patients
treated with two-phase conformal CRT were known M1
(8% versus 2%) or unrecorded M stage (10% versus 4%).
In total, 232 (96%) patients received full dose radio-
therapy to primary and prophylactic nodes. Of the 40 cen-
tres, 38 treated at least one patient with IMRT. Of the seven
patients who had radiation to a reduced dose, one received
treatment with palliative intent, three had T1 tumours or T2tumours after excision, one was frail and elderly, two were
elderly with a T1 or T2 post-excision tumour. Seven of the
242 (3%) did not undergo prophylactic inguinal node irra-
diation; four were T1, two after excision of a T2 and one
patient chose to discontinue treatment early due to toxicity.
Of those undergoing full dose inverse planned radiotherapy
to primary tumour and all prophylactic nodes, 157 (87%)
underwent treatment as described in the UK guidance
document. Of those who did not receive treatment as per
guidance; 21 (12%) received doses based on the RTOG 0529
publication, one delivered 50 Gy in 25 fractions and the last
delivered a two-phase technique with ACT2 doses to the
nodes in 17 fractions. Figure 1 illustrates the breakdown of
radiotherapy doses, volumes and techniques.
Chemotherapy regimens are given in Table 3. Those pa-
tients who did not receive chemotherapy were due to frailty
(one), T1 disease (one), age (one), the palliative nature of
radiotherapy (one), ongoing pelvic abscesses (one), cardiac
history and advancing age (one). In two patients (aged 70 and
81years),noreason forwithholdingchemotherapywasgiven.
For the purposes of assessment and comparisons of acute
toxicity, four groups were assessed: (A) data from the ACT2
publication; (B) all patients in the audit; (C) patients in the
audit treated with full dose radiotherapy including inguinal
nodes, using two-phase conformal CRT; and (D) patients in
the audit, treated with full dose radiotherapy including
inguinal nodes, with IMRT using UK guidance. The data on
gaps and discontinuation were based on the whole dataset.
The acute toxicity assessment was based on 199 and 192
patients where complete data were submitted for non-
haematological and haematological toxicity, respectively.
Table 4 details the toxicity.
The median treatment time in the ACT2 trial was 38 days
and in the three groups in the audit was 39 days (all pa-
tients), with 39 and 38 days for two-phase conformal CRT
and IMRT, respectively. The number of interruptions in
radiotherapy treatment was 15% in ACT2 and in the audit
groups 7%, 7% and 4%. The number of patients completing
the planned radiotherapy dose (irrelevant of gaps) in the
audit groups were 90% and 96%. The number of patients
completing chemotherapy was 77% in ACT2 and in the audit
groups 83%, 88%, 83%, respectively. Although these results
were an improvement over those reported in ACT2 in terms
of reduced interruptions and improved completion of
treatment, differences between patients treated with two-
phase conformal CRT and IMRT were not statistically
different (Fishers exact test P ¼ 0.3021 for interruptions,
P ¼ 0.1777 for completion of radiotherapy and P ¼ 0.667
for completion of chemotherapy). Treatment-related
deaths were <1% in ACT2 and <1%, 4%, and 0% in the
audit groups. These are documented in Table 5.Discussion
To our knowledge no prospective, comprehensive audit
of anal cancer practice has occurred to date. This audit gives
a comprehensive representation of current anal radio-
therapy practice, over a short time period, across the UK.
Table 1
Patient demographics
ACT2 trial* All UK audit
patients
Two-phase
conformal CRT
in UK auditz
IMRT as per
guidance
in UK auditz
(n ¼ 246y) (n ¼ 242) (n ¼ 52) (n ¼ 157)
Age (years), median (range) 60 62 (29e90) 59 (38e87) 62 (29e88)
Age <65 years 75% 140 (58%) 30 (58%) 93 (59%)
Age  65 years 25% 102 (42%) 22 (42%) 64 (41%)
Gender
Male 38% 64 (26%) 11 (21%) 47 (30%)
Female 62% 178 (74%) 41 (79%) 110 (70%)
Pre-treatment colostomy
Yes 13% 38 (16%) 11 (21%) 24 (15%)
No 87% 204 (84%) 41 (79%) 133 (85%)
Pre-treatment PET/CT
Yes N/R 95 (39%) 19 (37%) 65 (41%)
No N/R 147 (61%) 33 (63%) 92 (59%)
HIV status
Positive N/R 8 (3%) 1 (2%) 7 (4%)
Negative N/R 84 (35%) 11 (21%) 67 (43%)
Not performed N/R 150 (62%) 40 (77%) 83 (53%)
Smoking status
Current smoker N/R 58 (24%) 21 (40%) 38 (24%)
Ex-smoker (>6 months) N/R 46 (19%) 9 (17%) 30 (19%)
Never smoked N/R 95 (39%) 16 (31%) 60 (38%)
Do not know N/R 43 (18%) 6 (12%) 29 (18%)
CRT, chemoradiotherapy; IMRT, intensity-modulated radiotherapy; PET/CT, positron emission tomography/computed tomography.
* Data from the arm receiving mitomycin concurrently and no maintenance chemotherapy.
y Patients in the mitomycin, no maintenance were used for demographic comparison.
z Excluding patients without inguinal irradiation.
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tumour demographic data in a similar population, the data
captured in a clinical trial tends to reﬂect a ﬁtter population
with a higher performance status, which may not represent
routine clinical practice.
A number of factors prompted a national audit. The RCR
survey showed the sporadic and heterogeneous imple-
mentation of IMRT in independent centres without any
uniformed controlled roll-out, raising concerns due to the
quality assurance problems encountered in the RTOG 0529
trial. The implementation of IMRT around the UK was car-
ried out with informal mentoring between centres rather
than a formal quality assurance programme. The planned
collection of outcome data for audit patients will report
IMRT outcomes. This acts as an objective quality assurance
tool as if the delivery was carried out appropriately the
outcomes should be comparable with two-phase conformal
[AQ1] treatment. Furthermore, the forthcoming PLATO trial
(PersonaLising Anal cancer RadioTherapy dOse,
ISRCTN88455282) [22,23], funded by Cancer Research UK,
will require IMRT for anal cancer as standard. This is a
platform of studies incorporating ACT3 (testing low dose
involved ﬁeld CRT for patients with close surgical margins);
ACT4, a randomised phase II trial comparing standard CRT
with reduced dose CRT in patients with T1e2 (up to 4 cm)
N0 disease and ACT5, a seamless pilot/phase II/III trial
comparing standard CRT dose escalation using a synchro-
nous integrated boost.The patient demographics are similar to those docu-
mented in ACT2 with the exception of an older population
in the audit as expected due to the inclusion of all patients
irrespective of their performance status, co-morbidity and
treatment intent. Seventeen per cent of patients had an
unknown smoking status. In anal cancer, smoking status is a
prognostic factor [24,25] and the toxicity of radiotherapy
treatment is reported to be higher in those who continue to
smoke in other tumour types [26e29]. Therefore it is vital
that smoking status is documented and smoking cessation
advice given. The smoking rate in the audit (24%) exceeds
the national smoking incidence of 19% [30]. The imbalance
between the two-phase conformal CRT group (21/52
conﬁrmed current smokers as opposed to only 38/119 in
the group receiving IMRT) will be important when
analysing outcome data. The next step is further
investigation into the inﬂuence of smoking and work to
assess and improve, if appropriate, counselling regarding
smoking cessation. Another possible prognostic factor is
the histological differentiation of the tumour [31e33]. In
20% of cases this was not reported or available and another
factor that could be improved on. Finally, on patient/tumour
demographics, more recent National Institute for Health
and Care Excellence (NICE) guidance suggests that all pa-
tients with a diagnosis of anal cancer should be tested for
HIV [34,35] and this audit suggests further action is
required to improve this measure. The number of patients
undergoing a staging positron emission tomography/
Table 2
Tumour demographics
ACT2 trial* All UK audit
patients
Two-phase conformal
CRT in UK auditz
IMRT as per guidance
in UK auditz
(n ¼ 246y) (n ¼ 242) (n ¼ 52) (n ¼ 157)
Tumour type
Squamous 95% 240 (99%) 52 (100%) 155 (99%)
Adenocarcinoma 0% 1 (0.004%) 0 1 (0.006%)
Small cell carcinoma 0% 1 (0.004%) 0 1 (0.006%)
Unknown 5% 0 0 0
Level of differentiation
Well 12% 15 (6%) 2 (4%) 11 (7%)
Moderately 41% 96 (40%) 19 (37%) 63 (40%)
Poorly 30% 82 (34%) 18 (35%) 50 (32%)
Unknown 17% 49 (20%) 13 (25%) 33 (21%)
Site of primary tumour
Canal 82% 184 (76%) 37 (71%) 122 (78%)
Verge 15% 25 (10%) 7 (14%) 14 (9%)
Distal Rectum 0% 20 (8%) 7 (14%) 11 (7%)
Peri-anal skin 0% 9 (4%) 1 (2%) 7 (4%)
No primary identiﬁed 0% 2 (1%) 0 2 (1%)
Other 2% 2 (1%) 0 1 (1%)
T stage
T1 10% 28 (12%) 5 (10%) 15 (10%)
T2 40% 99 (41%) 22 (42%) 66 (42%)
T3 33% 61 (25%) 16 (31%) 39 (25%)
T4 13% 52 (21%) 9 (17%) 35 (22%)
Tx 4% 2 (1%) 0 2 (1%)
N stage
Negative 63% 120 (50%) 24 (46%) 74 (47%)
Positive 31% 122 (50%) 28 (54%) 83 (53%)
Nx 5% 0 0 0
M stage
M0 100% 221 (91%) 43 (83%) 148 (94%)
M1 0% 9 (4%) 4 (8%) 3 (2%)
Mx N/R 12 (5%) 5 (10%) 6 (4%)
CRT, chemoradiotherapy; IMRT, intensity-modulated radiotherapy.
* Data from the arm receiving mitomycin concurrently and no maintenance chemotherapy.
y Patients in the mitomycin, no maintenance were used for demographic comparison.
z Excluding patients without inguinal irradiation.
Fig 1. Flow diagram of radiotherapy doses, volumes and techniques.
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Table 3
Chemotherapy regimens
UK audit
(n ¼ 242)
Chemotherapy regimen
MMC 5-FU 156 (64.5%)
MMC capecitabine 68 (28.1%)
Cisplatin/5-FU 3 (1.2%)
MMC alone 1 (0.4%)
5-FU alone 1 (0.4%)
Capecitabine alone 2 (0.8%)
Cisplatin/Etoposide 2 (0.8%)
No chemotherapy 8 (3.3%)
Cisplatin alone 1 (0.4%)
MMC, mitomycin; 5-FU, 5-ﬂuorouracil.
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of validation of this modality in anal cancer. The recent
NCCN guidelines have only just incorporated PET/CT into
the workup of patients and even still only suggests ‘PET
should be considered’ [36].
The audit also highlights the variability ofmanagement in
early disease. The dose currently used in T1 and excised T2
tumours is currently heterogeneous. In T1 N0 tumours, 16
patients received 50.4 Gy in 28 fractions, and one patient
each received the following doses: 36 Gy in 20 fractions,
40 Gy in 25 fractions, 30 Gy in 10 fractions and 52 Gy in 26
fractions in a split course treatment. Of the T2 N0 tumoursTable 4
Comparison of grade 3þ4 acute toxicity during chemoradiotherapy (C
patients undergoing ACT2 regimen and UK audit patient treated in kee
ACT2 trial* All UK audit p
(n ¼ 199
non-haematol
(n ¼ 472y) n ¼ 192
haematologica
Non-haematologicalx 294 (62%) 87 (44%)
Gastrointestinal 75 (16%) 26 (13%)
Nausea 10 (2%) 6 (3%)
Vomiting 9 (2%) 4 (2%)
Diarrhoea 44 (9%) 18 (9%)
Stomatitis 14 (3%) 5 (3%)
Other gastrointestinal 16 (3%) 1 (1%)
Skin 228 (48%) 60 (30%)
Pain 122 (26%) 28 (14%)
Cardiac 7 (1%) 3 (1%)
Other non-haematological 34 (7%) 8 (4%)
Haematologicalx 124 (26%) 31 (16%)
Neutrophils 112 (24%) 25 (13%)
Platelets 21 (4%) 13 (7%)
Haemoglobin 2 (<1%) 2 (1%)
Febrile Neutropenia 15 (3%) 2 (1%)
Any toxic effectx 334 (71%) 104 (52%)
* Only the highest grade is counted and patients with more than one
y Patients in the mitomycin/5-ﬂuorouracil arm only were used for to
z Numbers and percentages based on patients with submitted toxicit
x Patients with more than one toxic effect counted only once.post excision two patients received 50 Gy in 28 fractions,
whereas one received 40 Gy in 28 fractions. This heteroge-
neity in dose makes outcomes in these groups difﬁcult to
assess. This is probably due to a lack of clear guidance or
evidence in this setting. PLATO will address this issue with
two of the studies under the PLATO umbrella investigating
these patients. Regarding the issue ofwhether to treat nodes
prophylactically in T1/T2 tumours, neither NCCN nor ESMO-
ESSO-ESTRO guidance offers speciﬁc guidance due to a lack
of sufﬁcient evidence. TheUK IMRTguidance suggests that in
T1 tumours theremay be patients where prophylactic nodal
irradiation is not required. However, due to conﬂicting re-
sults in the literature regarding withholding prophylactic
inguinal node irradiation in T2 tumours we suggest that T2
tumours do receive prophylactic nodal irradiation. Inguinal
relapse rates in patients treated without prophylactic irra-
diation are reported in up to 22.5% [37e41].
UK IMRT guidance is in keeping with NCCN and ESMO-
ESSO-ESTRO guidance, which suggests that mitomycin/5-
ﬂuorouracil or mitomycin/capecitabine should be used
concurrently with radiotherapy [36,42]. ESMO guidance
notes that cisplatin, single agent or triplet combination,
should not be used without good reason [43]. Ninety-three
per cent of patients were treated according to that guidance.
The few delivering single agent have noted that this was
due to co-morbidities. Those using cisplatin have not
documented reasons and it may be appropriate to investi-
gate the rationale behind this.RT) seen in the ACT2 publication, all UK audit patients, UK audit
ping with UK intensity-modulated radiotherapy (IMRT) guidance
atients Two-phase
conformal CRT
in UK audit
IMRT as per guidance
in UK audit
ogical;
(n ¼ 127
non-haematological;
l*z)
(n ¼ 45*z) n ¼ 120 haematological*z)
22 (49%) 51 (40%)
5 (11%) 17 (13%)
2 (4%) 4 (3%)
1 (2%) 3 (2%)
2 (4%) 13 (10%)
1 (2%) 3 (2%)
0 1 (1%)
18 (40%) 32 (25%)
6 (13%) 16 (13%)
0 3 (2%)
2 (4%) 6 (5%)
6 (13%) 21 (18%)
5 (11%) 15 (13%)
3 (7%) 9 (8%)
0 2 (2%)
0 1 (1%)
25 (54%) 62 (48%)
toxic effect of a particular grade were counted only once.
xicity comparison.
y.
Table 5
Comparison of radiotherapy interruptions, chemotherapy completion and treatment deaths seen in the ACT2 publication, all UK audit
patients, UK audit patients undergoing ACT2 regimen and UK audit patients treated in keeping with UK intensity-modulated radiotherapy
(IMRT) guidance
Percentage (with 95% conﬁdence interval) ACT2 trial All UK audit
patients
Two-phase
conformal CRT
in UK audit
IMRT as per
guidance
in UK audit
n 940* 242 52 157
Radiotherapy courses with interruptions 15% N/Ay 4 (8%) 7 (4%)
Patients completing planned
radiotherapy dose (irrelevant of gaps)
N/R 227 (94%) 47 (90%) 150 (96%)
Patients completing planned chemotherapy 77% 201 (83%) 45 (87%) 131 (83%)
Treatment deaths <1% 2 (1%) 2 (4%) 0
* Data from all patients within ACT2 were used for comparison as data for speciﬁc groups were not available.
y As includes palliative and lower dose patients not calculated.
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cording to ESMO-ESSO-ESTRO with a recommendation that
a reduction in treatment intensity should not be based on
age alone but on a combination of co-morbidity and per-
formance status [42]. There were 89% and 78% of patients
over 75 years, who received full dose radiotherapy and
CRT, respectively, which is encouraging. Performance status
was not speciﬁcally requested and as such we cannot offer a
reasonwhy seven patients had reduced intensity treatment.
Charnley et al. [44] published a small series using a reduced
regimen of CRT for elderly and frail patients and showed
excellent outcomes. However, in our audit a variety of
different reduced dose CRT regimens was used. Further
investigation of reduced intensity CRT in elderly patients
with poor performance status or co-morbidities could
inform guidance in this group.
NRIG recommendations would suggest that all patients
who would beneﬁt from IMRT should receive treatment
with this technique. Due to the results of the RTOG 0529
study, node-positive patients will probably have reduced
toxicity with IMRT and as such IMRT should be imple-
mented, delivered and audited, to assess toxicity, in this
group. The limitations to IMRT in the survey noted: capac-
ity, expertise and time; as limiting factors to implementa-
tion. With the UK guidelines, additional education and
support available with UK wide implementation we can
address expertise. However, time and capacity are local is-
sues that will need solutions to achieve the NRIG recom-
mendation. It is encouraging that 87% of those treated with
IMRT used the UK IMRT guidance. We hope publication of
audit results will encourage the remaining few centres who
practise outside the guidance to ensure homogeneous de-
livery and therefore assessment of outcomes using IMRT.
Our ﬁnding in this treated population-based audit is that
acute toxicity is reduced in comparisonwith that reported in
the ACT2 trial. This ﬁnding is similar to the ﬁndings of the
RTOG 0529 trial, where acute toxicity was reduced in com-
parisonwith RTOG 9811when delivered to 52 patients from
38 centres. It is interesting that the skin toxicity seems to be
reduced through the use of IMRT (40% grade 3/4 in the two-
phase conformal CRT group as compared with 25% in the
IMRT treated patients, although not reaching statisticalsigniﬁcance with such relatively small numbers, x2
P ¼ 0.846), which is a similar ﬁnding to the RTOG 0529
study. The RTOG study chose not to power the trial on
reduction in dermatological toxicity as they felt that the
skin around the anal verge will probably continue to
receive a similar dose with both techniques and as such a
similar toxicity grading. However, the dose to the inguinal
creases, which was previously a major source of morbidity,
will be signiﬁcantly reduced. This differentiation between
toxicity at the two sites cannot be identiﬁed from this audit
or the RTOG trial as all dermatological toxicity was graded
together, but we could hypothesis this is the cause of the
reduction in acute dermatitis.
Relative rates of diarrhoea and haematological grade 3/4
toxicity seemed to differ between the two-phase conformal
CRT and IMRT treated cohorts, although none of these
reached statistical signiﬁcance, noting the relatively small
numbers in each group. The more objective measure of
frequency of treatment interruptions was also reduced,
although again acknowledging that these are non-
randomised data and differences in patient demographics
(e.g. greater number of M1 patients in the two-phase
conformal CRT group) may also contribute to differences
in treatment tolerability and decision making. The main
differences between the UK IMRT guidance and two-phase
conformal [AQ1] are that the UK IMRT guidance allowed
the use of capecitabine and the radiotherapy delivery
technique. The increased grade 3 diarrhoea may be as a
result of the capecitabine or the different radiotherapy
technique. The increased thrombocytopenia with IMRT is
more likely due to the dose-bathing that can occur due to
the technique, as capecitabine is not associated with
increased thrombocytopenia when used with pelvic radio-
therapy [45]. The introduction of bone marrow constraints
in the UK guidance could be considered. Another factor that
must be considered when interpreting results is that the
measures to support patients through radiotherapy have
improved since ACT2 was undertaken; the signiﬁcant
improvement between toxicity in the published ACT2 data
and the two-phase conformal [AQ1]in our audit is probably
a reﬂection of this. The high volume centres in the audit
were also more likely to deliver treatment with IMRT and as
R. Muirhead et al. / Clinical Oncology 29 (2017) 188e197 195such the set up for support to minimise side-effects may
have had some effect on the reduced toxicity. Further
analysis of the data and a safety phase in ACT5 of PLATO
study are planned to investigate the toxicity further.
There are limitations to this prospective audit. The
annual incidence of anal cancer in the UK is about 1000
patients [46], as such we have captured over a 6 month
period about half of all presenting patients. Although
response rates to the audit, per centre, were 71%, which is
comparable with other national RCR audits, the submission
of 50% of all cases treated over the audit period is less than
previous audits [47,48]. The authors hypothesise that as the
audit was entitled ‘The implementation of IMRT in anal
cancer’, centres probably submitted more IMRT cases than
conformal or palliative cases. As such, although the data
may not represent overall anal cancer treatment, the IMRT
ﬁndings are probably robust. Due to the multidisciplinary
input of data and multiple patients from each centre there
may be minor errors in data input. There was an absence of
classiﬁcations for pathology and anatomy given to centres.
Therefore the data received are the clinicians’ understand-
ing of the pathology and anatomy. In addition, due to a
limited ability to clarify data submitted, some assumptions
weremade, which are all described above. However, in view
of the rarity of anal cancer and the lack of data regarding
capecitabine versus 5-ﬂuorouracil beyond phase II studies,
this dataset offers the ability to make some important ob-
servations in this disease during the implementation of
IMRT and the set-up of subsequent clinical studies.
Future work will include further assessment of the acute
toxicity data as the richness of information may contribute
relevant information to further guidance and PLATO. In
addition we plan to collect clinical response rates at 3
months and disease-free survival at 1 year to ensure clinical
outcomes are maintained and repeat the EORTC question-
naire at 1 year, in order to obtain comprehensive data on
long-term toxicity and patient-reported outcomes in a
routine anal cancer population.
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